Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 11/20 | 0.61 |
| ▸ | HSP90AB1 | P08238 | 10/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | NUDT1 | P36639 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CDC7 | O00311 | 1/20 | 0.45 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.45 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
| ▸ | PAK4 | O96013 | 1/20 | 0.45 |
| ▸ | PIM1 | P11309 | 1/20 | 0.45 |
| ▸ | PRKACA | P17612 | 1/20 | 0.45 |
| ▸ | GRK5 | P34947 | 1/20 | 0.45 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.45 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.45 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.45 |
| ▸ | CDK8 | P49336 | 1/20 | 0.45 |
| ▸ | CLK2 | P49760 | 1/20 | 0.45 |
| ▸ | GSK3A | P49840 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17325860 | 0.87 | NUDT1 (0.51) | HSP90AA1HSP90AB1NUDT1KMT2ADYRK1A | |
| SCHEMBL15757130 | 0.87 | NUDT1 (0.64) | HSP90AA1HSP90AB1KDM4ENUDT1KMT2A | |
| SCHEMBL3952089 | 0.87 | HSP90AA1 (0.70) | HSP90AA1HSP90AB1KDM4ENUDT1KMT2A | |
| SCHEMBL29571104 | 0.87 | HSP90AA1 (0.70) | HSP90AA1HSP90AB1KDM4ENUDT1KMT2A | |
| SCHEMBL4281168 | 0.83 | HSP90AA1 (0.75) | HSP90AA1HSP90AB1KDM4ENUDT1KMT2A | |
| SCHEMBL22501986 | 0.83 | HSP90AA1 (0.66) | HSP90AA1HSP90AB1KDM4EKMT2AADCY10 | |
| SCHEMBL15756934 | 0.82 | NUDT1 (0.77) | HSP90AA1HSP90AB1NUDT1ROCK1CLK4 | |
| Hydrochloric Acid SCHEMBL22502036 | 0.81 | HSP90AA1 (0.64) | HSP90AA1HSP90AB1KDM4EKMT2AADCY10 | |
| SCHEMBL30862038 | 0.81 | HSP90AA1 (0.54) | HSP90AA1HSP90AB1KDM4ENUDT1KMT2A | |
| SCHEMBL29124574 | 0.81 | HSP90AA1 (0.54) | HSP90AA1HSP90AB1KDM4ENUDT1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2925744-B1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES FOR TREATMENT OF CANCER | THOMAS HELLEDAYS STIFTELSE FOER MEDICINSK FORSKNING (SE) | 2020-12-30 | — | — | EP | disclosed |
| EP-2925744-B1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES FOR TREATMENT OF CANCER | THOMAS HELLEDAYS STIFTELSE FOER MEDICINSK FORSKNING (SE) | 2020-12-30 | — | — | EP | disclosed |
| US-10632125-B2 | MTH1 inhibitors for treatment of inflammatory and autoimmune conditions | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2020-04-28 | — | — | US | disclosed |
| US-10632125-B2 | MTH1 inhibitors for treatment of inflammatory and autoimmune conditions | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2020-04-28 | — | — | US | disclosed |
| US-10179790-B2 | MTH1 inhibitors for treatment of cancer | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2019-01-15 | — | — | US | disclosed |
| US-10179790-B2 | MTH1 inhibitors for treatment of cancer | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2019-01-15 | — | — | US | disclosed |
| US-10174029-B2 | Pyrimidine-2,4-diamine derivatives for treatment of cancer | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2019-01-08 | — | — | US | disclosed |
| US-10174029-B2 | Pyrimidine-2,4-diamine derivatives for treatment of cancer | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2019-01-08 | — | — | US | disclosed |
| US-20190000856-A1 | MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS | THOMAS HELLEDAYS STIFTELSE FOER MEDICINSK FORSKNING (SE) | 2019-01-03 | — | — | US | disclosed |
| US-10064869-B2 | MTH1 inhibitors for treatment of inflammatory and autoimmune conditions | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2018-09-04 | — | — | US | disclosed |
| WO-2015187089-A1 | MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2015-12-10 | — | — | WO | disclosed |
| WO-2015187089-A1 | MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2015-12-10 | — | — | WO | disclosed |
| EP-2925744-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES FOR TREATMENT OF CANCER | Thomas Helledays Stiftelse För Medicinsk Forskning (SE) | 2015-10-07 | — | — | EP | disclosed |
| WO-2014084778-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES FOR TREATMENT OF CANCER | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2014-06-05 | — | — | WO | disclosed |
| WO-2014084778-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES FOR TREATMENT OF CANCER | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2014-06-05 | — | — | WO | disclosed |
| US-20090215777-A1 | Pyrimidine Derivatives As HSP90 Inhibitors | ASTEX THERAPEUTICS LTD. (GB) | 2009-08-27 | — | — | US | disclosed |
| US-20090215777-A1 | Pyrimidine Derivatives As HSP90 Inhibitors | ASTEX THERAPEUTICS LTD. (GB) | 2009-08-27 | — | — | US | disclosed |
| US-20090215777-A1 | Pyrimidine Derivatives As HSP90 Inhibitors | ASTEX THERAPEUTICS LTD. (GB) | 2009-08-27 | — | — | US | disclosed |
| EP-2049497-A2 | PYRIMIDINE DERIVATIVES AS HSP90 INHIBITORS | Astex Therapeutics Limited (GB) | 2009-04-22 | — | — | EP | disclosed |
| WO-2006123165-A2 | PYRIMIDINE DERIVATIVES AS HSP90 INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10179790-B2 | MTH1 inhibitors for treatment of cancer | MTHFD1, MTHFD2, DPYD | HSP90AA1 458/4885HSP90AB1 346/4885KDM4E 3062/4885 |
| US-10174029-B2 | Pyrimidine-2,4-diamine derivatives for treatment of cancer | DPYD, MTHFD1, TYMS | HSP90AA1 1619/4885HSP90AB1 1503/4885KDM4E 2454/4885 |
| US-20190000856-A1 | MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS | MTHFD1, MTHFD2, TPMT | HSP90AA1 385/4885HSP90AB1 249/4885KDM4E 3971/4885 |
| US-10632125-B2 | MTH1 inhibitors for treatment of inflammatory and autoimmune conditions | MTHFD1, MTHFD2, TPMT | HSP90AA1 385/4885HSP90AB1 249/4885KDM4E 3971/4885 |
| US-10064869-B2 | MTH1 inhibitors for treatment of inflammatory and autoimmune conditions | MTHFD1, MTHFD2, TPMT | HSP90AA1 385/4885HSP90AB1 249/4885KDM4E 3971/4885 |
| US-20090215777-A1 | Pyrimidine Derivatives As HSP90 Inhibitors | HSP90AB1, HSP90AB2P, HSP90B1 | HSP90AA1 4/4885HSP90AB1 1/4885KDM4E 4124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.